CD4 and neoplasm: From an immunological perspective, IDH1(R132H) represents a potential immunotherapy target because it is a tumor-specific potential neoantigen that is indeed presented in major histocompatibility complex class II (MHCII) and can, thus, evoke a robust immune response in CD4+ T cells [114].